Early-onset type 2 diabetes: the next major diabetes transition
- PMID: 40570862
- DOI: 10.1016/S0140-6736(25)00830-X
Early-onset type 2 diabetes: the next major diabetes transition
Erratum in
-
Department of Error.Lancet. 2025 Oct 11;406(10512):1564. doi: 10.1016/S0140-6736(25)02057-4. Lancet. 2025. PMID: 41076295 No abstract available.
Abstract
The incidence of early-onset type 2 diabetes is increasing, with a growing number of cases now occurring in children, adolescents, and young adults. This transition is primarily driven by the rising prevalence of obesity in younger populations, especially in high-income countries. However, the relationship between obesity and early-onset type 2 diabetes varies across ethnic groups, with some populations exhibiting a higher risk at lower BMI thresholds, possibly due to differences in insulin resistance and β-cell function. Socioeconomic factors further shape disease patterns, with early-onset type 2 diabetes disproportionately affecting lower-income populations in high-income settings, whereas in low-income and middle-income countries, economic development and urbanisation have contributed to increasing incidence among more affluent groups. The consequences of this transition to early-onset type 2 diabetes are severe, with accelerated disease progression, heightened risks of microvascular and macrovascular complications, and considerable societal and health-care burdens compared with later-onset disease. Given the continuing rise in childhood and adolescent obesity, the incidence of early-onset type 2 diabetes is expected to increase further, placing mounting pressure on health-care systems worldwide. In the first of three papers in this Series, we examine global trends in the incidence and prevalence of early-onset type 2 diabetes, identify key drivers of this transition to diagnosis at younger ages, and review the evidence for risk factors both at population and individual level.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests SM has received speaker honoraria from Lilly UK, Sanofi, and Menarini. All other authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
